Compare CCHH & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCHH | LNAI |
|---|---|---|
| Founded | 2015 | N/A |
| Country | Malaysia | United States |
| Employees | N/A | 29 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2M | 11.9M |
| IPO Year | N/A | N/A |
| Metric | CCHH | LNAI |
|---|---|---|
| Price | $0.66 | $0.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.2M | ★ 31.9M |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $43.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $0.15 |
| 52 Week High | $15.39 | $1.66 |
| Indicator | CCHH | LNAI |
|---|---|---|
| Relative Strength Index (RSI) | 47.55 | 46.54 |
| Support Level | $0.62 | $0.35 |
| Resistance Level | $0.68 | $1.04 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 26.55 | 26.61 |
CCH Holdings Ltd operates a hotpot restaurant chain in Malaysia, specializing in chicken hotpot and fish head hotpot, mainly under two brand, namely Chicken Claypot House and Zi Wei Yuan, owned by the wholly owned subsidiaries of the Company. The Company conducts its operations through its wholly owned subsidiaries in Malaysia and is engaged as a restaurant operator, licensor and loyalty owner, and general trader. Currently, the Group has developed a restaurant chain including approximately 15 company-owned restaurant outlets, 13 franchised restaurant outlets in Malaysia, and 4 franchised restaurant outlets outside Malaysia.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.